Top

Published in:

Open Access 01-07-2017 | Laboratory Investigation

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations

Authors: S. Balendran, S. Liebmann-Reindl, A. S. Berghoff, T. Reischer, N. Popitsch, C. B. Geier, L. Kenner, P. Birner, B. Streubel, M. Preusser

Published in: Journal of Neuro-Oncology | Issue 3/2017

Abstract

Ovarian cancer represents the most common gynaecological malignancy and has the highest mortality of all female reproductive cancers. It has a rare predilection to develop brain metastases (BM). In this study, we evaluated the mutational profile of ovarian cancer metastases through Next-Generation Sequencing (NGS) with the aim of identifying potential clinically actionable genetic alterations with options for small molecule targeted therapy. Library preparation was conducted using Illumina TruSight Rapid Capture Kit in combination with a cancer specific enrichment kit covering 94 genes. BRCA-mutations were confirmed by using TruSeq Custom Amplicon Low Input Kit in combination with a custom-designed BRCA gene panel. In our cohort all eight sequenced BM samples exhibited a multitude of variant alterations, each with unique molecular profiles. The 37 identified variants were distributed over 22 cancer-related genes (23.4%). The number of mutated genes per sample ranged from 3 to 7 with a median of 4.5. The most commonly altered genes were BRCA1/2, TP53, and ATM. In total, 7 out of 8 samples revealed either a BRCA1 or a BRCA2 pathogenic mutation. Furthermore, all eight BM samples showed mutations in at least one DNA repair gene. Our NGS study of BM of ovarian carcinoma revealed a significant number of BRCA-mutations beside TP53, ATM and CHEK2 mutations. These findings strongly suggest the implication of BRCA and DNA repair malfunction in ovarian cancer metastasizing to the brain. Based on these findings, pharmacological PARP inhibition could be one potential targeted therapeutic for brain metastatic ovarian cancer patients.

Available only for authorised users

Nafisi H, Cesari M, Karamchandani J, Balasubramaniam G, Keith JL (2015) Metastatic ovarian carcinoma to the brain: an approach to identification and classification for neuropathologists. Neuropathology 35(2):122–129. doi:10.1111/neup.12172 CrossRefPubMed

Hollis RL, Gourley C (2016) Genetic and molecular changes in ovarian cancer. Cancer Biol Med 13(2):236–247. doi:10.20892/j.issn.2095-3941.2016.0024 CrossRefPubMedPubMedCentral

Bookman MA (2016) Optimal primary therapy of ovarian cancer. Ann Oncol 27(Suppl 1):i58–i62. doi:10.1093/annonc/mdw088 CrossRefPubMed

Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, Chen VW (2003) Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer 97(10 Suppl):2676–2685. doi:10.1002/cncr.11349 CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 CrossRef

Lee JY, Yoon JK, Kim B, Kim S, Kim MA, Lim H, Bang D, Song YS (2015) Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer 15:85. doi:10.1186/s12885-015-1077-4 CrossRefPubMedPubMedCentral

Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3):1053–1064. doi:10.2353/ajpath.2010.100105 CrossRefPubMedPubMedCentral

Larson DM, Copeland LJ, Moser RP, Malone JM Jr, Gershenson DM, Wharton JT (1986) Central nervous system metastases in epithelial ovarian carcinoma. Obstet Gynecol 68(6):746–750PubMed

Barker GH, Orledge J, Wiltshaw E (1981) Involvement of the central nervous system in patients with ovarian carcinoma. Br J Obstet Gynaecol 88(7):690–694CrossRefPubMed

10.

Hardy JR, Harvey VJ (1989) Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol 33(3):296–300CrossRefPubMed

11.

Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A, Mammoliti S, Narducci F, Bergamini A, Scollo P, Biglia N, Breda E, Tamberi S, Marinaccio M, Angioli R, Salerno L, Eusebi MC, Loizzi V, Scambia G, Panici PB (2016) Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). Gynecol Oncol 143(3):532–538. doi:10.1016/j.ygyno.2016.09.025 CrossRefPubMed

12.

Preusser M, Berghoff AS, Koller R, Zielinski CC, Hainfellner JA, Liebmann-Reindl S, Popitsch N, Geier CB, Streubel B, Birner P (2015) Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. Eur J Cancer 51(13):1803–1811. doi:10.1016/j.ejca.2015.06.107 CrossRefPubMed

13.

Teckie S, Makker V, Tabar V, Alektiar K, Aghajanian C, Hensley M, Beal K (2013) Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival. Radiat Oncol 8:36. doi:10.1186/1748-717x-8-36 CrossRefPubMedPubMedCentral

14.

Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. doi:10.1038/nature10166 CrossRef

15.

Ab Mutalib NS, Syafruddin SE, Md Zain RR, Mohd Dali AZ, Mohd Yunos RI, Saidin S, Jamal R, Mokhtar NM (2014) Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach. BMC Res Notes 7:805. doi:10.1186/1756-0500-7-805 CrossRefPubMedPubMedCentral

16.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5(11):1164–1177. doi:10.1158/2159-8290.cd-15-0369 CrossRefPubMedPubMedCentral

17.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ (2013) Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 130(3):554–559. doi:10.1016/j.ygyno.2013.06.019 CrossRefPubMed

18.

Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF (2016) Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 34(20):2404–2415. doi:10.1200/jco.2016.66.6487 CrossRefPubMedPubMedCentral

19.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404. doi:10.1158/2159-8290.cd-12-0095 CrossRefPubMed

20.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. doi:10.1126/scisignal.2004088 CrossRefPubMedPubMedCentral

21.

Bender R, Lange S (2001) Adjusting for multiple testing–when and how? J Clin Epidemiol 54(4):343–349CrossRefPubMed

22.

Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S (2015) TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas. Gynecol Oncol 138(1):159–164. doi:10.1016/j.ygyno.2015.04.039 CrossRefPubMedPubMedCentral

23.

Mullany LK, Wong KK, Marciano DC, Katsonis P, King-Crane ER, Ren YA, Lichtarge O, Richards JS (2015) Specific TP53 mutants overrepresented in ovarian cancer impact CNV, TP53 activity, responses to nutlin-3a, and cell survival. Neoplasia 17(10):789–803. doi:10.1016/j.neo.2015.10.003 CrossRefPubMedPubMedCentral

24.

Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A (2016) BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget 7(2):1076–1083. doi:10.18632/oncotarget.6834 CrossRefPubMedPubMedCentral

25.

Rubin AF, Green P (2009) Mutation patterns in cancer genomes. Proc Natl Acad Sci USA 106(51):21766–21770. doi:10.1073/pnas.0912499106 CrossRefPubMedPubMedCentral

26.

Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, Fotia V, Romualdi C, Martini P, Noris M, Paracchini L, Craparotta I, Petrillo M, Milani R, Perego P, Ravaggi A, Zambelli A, Ronchetti E, D’Incalci M, Marchini S (2015) Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Ann Oncol 26(7):1363–1371. doi:10.1093/annonc/mdv164 CrossRefPubMed

27.

Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R (2014) Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 5(9):2349–2354. doi:10.18632/oncotarget.1946 CrossRefPubMedPubMedCentral

28.

Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ (2016) Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. Exp Mol Pathol 100(3):421–425. doi:10.1016/j.yexmp.2016.04.002 CrossRefPubMed

29.

O’Donovan PJ, Livingston DM (2010) BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31(6):961–967. doi:10.1093/carcin/bgq069 CrossRefPubMed

30.

Koul A, Loman N, Malander S, Borg A, Ridderheim M (2001) Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report. Gynecol Oncol 80(3):399–402. doi:10.1006/gyno.2000.6085 CrossRefPubMed

31.

Anacker DC, Moody CA (2016) Modulation of the DNA damage response during the life cycle of human papillomaviruses. Virus Res. doi:10.1016/j.virusres.2016.11.006 PubMed

32.

Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408(6811):433–439. doi:10.1038/35044005 CrossRefPubMed

33.

Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28(5):739–745. doi:10.1016/j.molcel.2007.11.015 CrossRefPubMed

34.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921. doi:10.1038/nature03445 CrossRefPubMed

35.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS (2016) DNA repair in prostate cancer: biology and clinical implications. Eur Urol. doi:10.1016/j.eururo.2016.08.037

36.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115. doi:10.1158/0008-5472.can-06-0140 CrossRefPubMed

37.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17(11):1579–1589. doi:10.1016/s1470-2045(16)30376-x CrossRefPubMed

38.

Moschetta M, George A, Kaye SB, Banerjee S (2016) BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 27(8):1449–1455. doi:10.1093/annonc/mdw142 CrossRefPubMed

39.

Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL (2016) Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol 27(6):1013–1019. doi:10.1093/annonc/mdw133 CrossRefPubMed

40.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16(1):87–97. doi:10.1016/s1470-2045(14)71135-0 CrossRefPubMed

41.

Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR (2011) Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 8(5):302–306. doi:10.1038/nrclinonc.2011.42 CrossRefPubMed

42.

Meehan RS, Chen AP (2016) New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 3:3. doi:10.1186/s40661-016-0024-7 CrossRefPubMedPubMedCentral

43.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. doi:10.1056/NEJMoa1611310

Title: Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations
Authors: S. Balendran
S. Liebmann-Reindl
A. S. Berghoff
T. Reischer
N. Popitsch
C. B. Geier
L. Kenner
P. Birner
B. Streubel
M. Preusser
Publication date: 01-07-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2459-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases

Evaluation of mitochondrial respiratory function in highly glycolytic glioma cells reveals low ADP phosphorylation in relation to oxidative capacity

MGMT promoter methylation status: time for a frank discussion

Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting

MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Analysis of surgical and MRI factors associated with cerebellar mutism